Literature DB >> 2874859

Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation.

F M Belpaire, M G Bogaert, P Mugabo, M T Rosseel.   

Abstract

The beta-blocking effect of 4 beta-adrenoceptor antagonists with different pharmacokinetic properties was studied after intravenous and intraportal administration to control rats and to rats with experimental inflammation. In rats with inflammation the effects of propranolol and oxprenolol, which are mainly bound to alpha 1-acid glycoprotein (alpha 1-AGP), were significantly less after intravenous administration, but not after intraportal administration. In contrast, for metoprolol and atenolol, which are only negligibly serum bound, no difference was observed between control rats and rats with inflammation for either route of administration. Total and unbound serum concentrations of propranolol were measured 20 min after intravenous and intraportal administration. After intravenous administration, in the rats with inflammation total concentrations of propranolol were more than twice, and unbound concentrations less than half those of control rats. After intraportal administration the total concentrations were 8 times, and the unbound concentrations 3 times higher in the rats with inflammation. There was a significant correlation between the beta-blocking effect and the unbound concentrations of propranolol after intravenous administration, but not after intraportal administration. The latter finding is probably because the unbound concentrations were supramaximal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874859      PMCID: PMC1916977          DOI: 10.1111/j.1476-5381.1986.tb10253.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Effects of inflammatory disease on plasma oxprenolol concentrations.

Authors:  M J Kendall; C P Quarterman; H Bishop; R E Schneider
Journal:  Br Med J       Date:  1979-08-25

3.  Plasma binding and the affinity of propranolol for a beta receptor in man.

Authors:  D G McDevitt; M Frisk-Holmberg; J W Hollifield; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

4.  beta-blocker plasma concentrations and inflammatory disease: clinical implications.

Authors:  R E Schneider; H Bishop
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 5.  Impaired drug metabolism in rats with adjuvant-induced arthritis: a brief review.

Authors:  M W Whitehouse; F J Beck
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

6.  High-performance liquid chromatographic determination of propranolol and 4-hydroxypropranolol in plasma.

Authors:  M T Rosseel; M G Bogaert
Journal:  J Pharm Sci       Date:  1981-06       Impact factor: 3.534

7.  Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum.

Authors:  F M Belpaire; M G Bogaert; M Rosseneu
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade.

Authors:  S A Bai; F P Abramson
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

9.  Studies on acute phase proteins of rat serum. II. Determination of the contents of 1 -acid glycoprotein, 2-macroglobulin, and albumin in serum from rats suffering from induced inflammation.

Authors:  J C Jamieson; F E Ashton; A D Friesen; B Chou
Journal:  Can J Biochem       Date:  1972-08

10.  Plasma propranolol concentrations and the erythrocyte sedimentation rate.

Authors:  R E Schneider; H Bishop; C F Hawkins
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

View more
  4 in total

1.  Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.

Authors:  S Urien; D Morin; A Renouard; I Rocher; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels.

Authors:  N Jauregizar; R Calvo; E Suarez; A Quintana; E Raczka; J C Lukas
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 3.  Plasma protein binding and pharmacological response.

Authors:  P du Souich; J Verges; S Erill
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

4.  Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart.

Authors:  Saeed Sattari; William F Dryden; Lise A Eliot; Fakhreddin Jamali
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.